HomeBest options strategy › RARE

Best Options Strategy for RARE

Di Dennis Bosmans · Aggiornato 2026-07-22 · 2 min di lettura · Avvertenza sui rischi

Looking for the best options strategy for Ultragenyx Pharmaceutical Inc. (RARE)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live RARE option chain right now, and a simple map from your view on RARE to the strategy that fits it. Model any of them in the calculator before you trade.

About Ultragenyx Pharmaceutical Inc.

# About Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical is a biopharmaceutical company developing and commercializing treatments for rare and ultra-rare genetic diseases. The company operates across North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific region. Its marketed products include Crysvita, a monoclonal antibody used for X-linked hypophosphatemia and tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for mucopolysaccharidosis VII; Dojolvi for long-chain fatty acid oxidation disorders; and Evkeeza for homozygous familial hypercholesterolemia. Beyond these approved therapies, Ultragenyx maintains a pipeline of candidates in advanced development, including several gene therapy programs in Phase 3 trials targeting conditions like osteogenesis imperfecta, Sanfilippo syndrome, glycogen storage disease, and ornithine transcarbamylase deficiency, plus an antisense therapy for Angelman syndrome.

The company generates revenue from its approved product sales while advancing its pipeline toward commercialization. Its business model relies on partnerships and licensing agreements with organizations including Kyowa Kirin,…

Today's top-scoring strategy for RARE

Our engine ranks defined-risk strategies on the live RARE chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.

Iron Condor neutral
Price: $27.70Implied volatility: 114%Expiration: 2026-08-21 (29d)
ActionQtyTypeStrikePremium
BuyPUT$12.5$0.10
SellPUT$20$1.45
SellCALL$35$1.95
BuyCALL$42.5$0.65
P/L at expiry vs today At expiry Today ±1σ
$0$30$61
Profitto massimo
$265
Perdita massima
−$485
Credito netto (incassato)
$265
Punto/i di pareggio
$17.35, $37.65
Position Greeks
Δ
−4.81
Γ
−3.646
Θ
4.99
ν
−2.56
Time decay (price held)
Implied-volatility skew

Simulazione

Simulazione prospettica di 6,000 traiettorie di prezzo lognormali fino alla scadenza — non è un backtest storico.

Percentuale di successo
78%
P/L medio
$119
Mediana
$265
Mov. atteso (1σ)
32%
5° pct
−$485
25° pct
$47
75° pct
$265
95° pct
$265

Analisi della strategia

Traiettorie di prezzo simulate (tempo × prezzo)
now $28BE $17BE $38$15$30$450d15d29d
$-476$-110$256

Greche vs prezzo

Δ — P/L in $ per ogni movimento di $1 del sottostante (esposizione equivalente in azioni).
Θ — P/L in $ al giorno dal decadimento temporale.
ν — P/L in $ per ogni +1% di volatilità implicita.
Γ — quanto velocemente cambia il delta per ogni movimento di $1.

Prezzo × volatilità (oggi)

−30%−15%IV+15%+30%
$35$54$35$18−$1−$21
$33$95$69$44$20−$5
$32$131$99$69$39$9
$30$162$125$89$54$20
$29$186$146$105$65$28
$28$201$159$115$72$32
$26$208$164$118$73$31
$25$204$160$113$67$24
$24$189$145$98$53$11
$22$160$118$74$31−$8
$21$117$78$38$0−$35
Analyze RARE in the calculator → Share this pick ↗

Live scan from 2026-07-22 · quotes delayed ~15 minutes

Backtest storico: come si sarebbe comportata una Iron Condor su RARE

Abbiamo simulato in modo approssimativo una Iron Condor su RARE che avresti aperto ripetutamente nell'ultimo anno (93 ingressi storici, ciascuno mantenuto fino alla scadenza), con i premi d'ingresso modellati tramite Black-Scholes. Ecco come sarebbe andata sulla reale storia dei prezzi di RARE — un backtest didattico, non una previsione dei rendimenti futuri.

Trade
93
Percentuale di successo
82%
P/L totale
$2454
Rendimento medio sul rischio
+10%
Trade migliore
$310
Trade peggiore
-$630
P/L cumulativo lungo il backtest

In via approssimativa: i premi d'ingresso sono modellati con Black-Scholes sulla base della volatilità realizzata trailing, mantenuti fino alla scadenza e regolati contro il reale prezzo di chiusura storico. Fill reali, volatilità implicita e slippage differiscono — consideralo come contesto indicativo, non come rendimento esatto.

Implied volatility

RARE is currently trading with high implied volatility, which makes its options expensive — and attractive to sell. On the options we scanned that was around 114% implied volatility, and higher implied volatility means richer premiums and wider expected moves.

Options on RARE currently price in about 114% implied volatility, versus roughly 59% the stock has actually realised over the past month. That makes options relatively expensive — an edge for strategies that sell premium, such as credit spreads and iron condors.

Off that volatility, the options market is pricing a move of about ±$8,95 (±32%) in RARE by 2026-08-21 — a range of roughly $18,76 to $36,65. Strikes inside that band hold most of the premium and see most of the action.

Across strikes, upside calls on RARE carry a higher implied volatility than downside puts — demand is tilted to the upside, which favours call spreads or selling cash-secured puts.

In evidenza dalla option chain di RARE: open interest, volume e skew

La option chain live di RARE mostra un rapporto put/call sull'open interest di 0.25 (bullish-leaning (more calls)), con una volatilità implicita at-the-money intorno al 107.9%. L'open interest si concentra sulla call a 40 — un classico "muro" di resistenza — e sulla put a 22.5, un "muro" di supporto: esattamente gli strike a cui gli scrittori di opzioni sono più esposti verso la scadenza.

Put/Call OI
0.25
Volume Put/Call
4.85
ATM IV
107.9%
Skew IV put–call
-41.7
Muro OI call
$40 · 2444
Muro OI put
$23 · 804
Call più attiva
$40 · 50
Put più attiva
$18 · 750
Strike più attivi (volume)
$10$28$45
Calls   Puts

Istantanea di open interest, volume e volatilità implicita per la scadenza scansionata più vicina — contesto, non un segnale di trading.

Insider trading su RARE (SEC Form 4)

Operazioni degli insider sul mercato aperto relative a RARE negli ultimi sei mesi circa, tratte dalle comunicazioni SEC Form 4. Gli acquisti sul mercato aperto sono il segnale più raro e più forte — le vendite di routine effettuate nell'ambito di piani prestabiliti sono frequenti, quindi leggi un dato di vendita netta tenendolo presente.

Acquisti sul mercato aperto
0 · —
Vendite sul mercato aperto
20 · $3.3M
Netto (acquisti − vendite)
−$3.3M
InsiderAzioneAzioniValoreData
Horn HowardVendita4698$156K2026-07-01
Sanders Corazon (Corsee) D.Vendita2000$50K2026-06-15
Parschauer Karah HerdmanVendita1899$47K2026-06-15
Horn HowardVendita4653$111K2026-06-01
SULIMAN SHEHNAAZVendita5740$144K2026-05-18
Crombez EricVendita344$9K2026-05-05

Fonte: comunicazioni SEC Form 4 tramite Finnhub. Solo acquisti (P) e vendite (S) sul mercato aperto — assegnazioni, esercizi di opzioni, donazioni e ritenute fiscali sono esclusi. Contesto informativo, non consulenza sugli investimenti.

Liquidity and tradeability

RARE options are thinly traded, with wide bid-ask spreads around 54,5% near the money that eat into any edge — favour simple single-leg or tight defined-risk trades, and always use limit orders.

Earnings & IV crush

RARE's next earnings report is due around 4 agosto 2026. Options that expire after it price in a binary move, so their implied volatility is elevated and usually collapses right after the announcement — an "IV crush". If your expiration falls before this date, the trade sidesteps the event.

With earnings roughly 13 days out, RARE's 114% implied volatility is inflated by event premium — and it usually collapses the moment results drop ("IV crush"). That rewards defined-risk premium sellers when the move stays muted, and punishes option buyers who paid the inflated price. Keep size small and risk defined through the report.

Key figures

Market cap
$2.7B
Beta (vs market)
0.31
52-week range
$18.29–$39.89 (44% up the range)
Short interest
17.0% of float · 5.4 days to cover

With 17.0% of RARE's float sold short, squeeze and gap risk are elevated — one reason its options can stay expensive.

How to choose an options strategy for RARE

Start with your outlook on RARE, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:

Bullish

You expect RARE to rise

Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.

Long Call → Bull Call Spread →

Bearish

You expect RARE to fall

Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.

Long Put → Bear Put Spread →

Neutral

You expect RARE to trade in a range

Sell an iron condor to collect premium while RARE stays between two strikes, or write a covered call against shares you already own.

Iron Condor → Covered Call →

⧉ Embed this free calculator on your site →

How we pick the best strategy

For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →

Open RARE in the free calculator →

Domande frequenti

What is the best options strategy for RARE?

It depends on your outlook. Bullish traders often use a long call or bull call spread on RARE; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.

Are RARE options liquid enough to trade?

Ultragenyx Pharmaceutical Inc. (RARE) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.

How much money do I need to trade RARE options?

Buying a single RARE call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.

Is this financial advice?

No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade RARE or any security. Do your own research.

Cosa fa Ultragenyx Pharmaceutical Inc.?

Ultragenyx Pharmaceutical Inc. (RARE) opera nel settore Biotechnology. La sezione "Informazioni su Ultragenyx Pharmaceutical Inc." qui sopra offre un quadro più completo di ciò che fa l'azienda e di come genera profitti.

Ultragenyx Pharmaceutical Inc. paga dividendi?

Qui non mostriamo un rendimento da dividendo confermato per Ultragenyx Pharmaceutical Inc., quindi consideralo incerto: prima di scrivere delle call controlla il dividendo attuale e la data di stacco cedola (ex-dividend) presso il tuo broker — una data di stacco imminente può innescare un'assegnazione anticipata sulle call scritte in-the-money.

Quando Ultragenyx Pharmaceutical Inc. pubblica gli utili?

I prossimi utili di Ultragenyx Pharmaceutical Inc. sono attesi intorno al 4 agosto 2026. La volatilità implicita di solito sale in avvicinamento alla pubblicazione e crolla bruscamente dopo (IV crush) — un aspetto importante per qualsiasi posizione in opzioni che mantieni oltre quella data.

Tickers related to RARE

Comparing RARE with similar names can help you choose the best options strategy:

AGIOAgios Pharmaceuticals, Inc.DNLIDenali Therapeutics Inc.RGNXREGENXBIO Inc.QUREuniQure N.V.

Informazioni sull’azienda

Sede
60 Leveroni Court, Novato, CA, 94949, United States
Settore
Biotechnology
Dipendenti
1371
CEO
Dr. Emil D. Kakkis M.D., Ph.D.
Telefono
415 483 8800
Sito web
www.ultragenyx.com

Best Options Strategy by Ticker →

Solo per uso didattico. Le quotazioni sono ritardate di circa 15 minuti e nulla di ciò che è riportato qui è consulenza finanziaria. Il trading di opzioni comporta un rischio sostanziale di perdita. Privacy · Terms.